Curis Inc. (CRIS)

2.01
NASDAQ : Health Technology
Prev Close 1.96
Day Low/High 1.91 / 2.07
52 Wk Low/High 0.60 / 2.90
Avg Volume 189.40K
Exchange NASDAQ
Shares Outstanding 33.20M
Market Cap 65.08M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Curis To Release Second Quarter 2010 Financial Results And Hold Conference Call On August 3, 2010

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its second quarter 2010 financial results on...

Curis Achieves Phase I Milestone Under Hsp90 Collaboration With Debiopharm

Curis, Inc. (NASDAQ: CRIS) announced today that its licensee Debiopharm S.

Curis Drug Fails Mid-Stage Colon Cancer Study: BioBuzz

The Curis cancer drug, GDC-0449, is partnered to Roche, which is also running studies in other cancer types.

Curis Announces Genentech’s Phase II Clinical Trial Results Of GDC-0449 In Combination With Avastin® And Chemotherapy In First-Line Metastatic Colorectal Cancer

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial...

Curis Announces Change To Presentation Time At ThinkEquity’s Mid Year Check-up On Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its presentation time for the upcoming...

Curis To Present At ThinkEquity’s Mid Year Check-up On Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the company will be presenting at ...

Curis, Inc. Announces Appointment Of Marc Rubin, M.D. To Its Board Of Directors

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the appointment of Marc Rubin, M.

Curis To Present At The Needham Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the company will be presenting at the Needham...

Curis To Present At The Jefferies 2010 Global Life Sciences Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the company will be presenting at the...

13 ASCO Stocks Presenting New Clinical Data

Here's the updated list of biotech and drug stocks that will be presenting new clinical data at this year's American Society of Clinical Oncology meeting.

Curis Added To NASDAQ Biotechnology Index

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has been selected for addition to the...

Curis To Present At The Rodman & Renshaw 6th Annual Global Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the company will be presenting at the Rodman...

Curis, Inc. Q1 2010 Earnings Call Transcript

Curis, Inc. Q1 2010 Earnings Call Transcript

Curis Reports First Quarter 2010 Financial Results

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended...

Curis Completes Enrollment Of CUDC-101 Phase I Clinical Trial

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has successfully completed enrollment and...

13 Biotech Stocks Presenting New Clinical Data

Here's a list of biotech and drug stocks that will be presenting new clinical data at this year's American Society of Clinical Oncology meeting.

Curis To Release First Quarter 2010 Financial Results And Hold Conference Call On May 6, 2010

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its first quarter financial results on ...

Curis Licensee Debiopharm Initiates Phase I Clinical Trial Of Hsp90 Inhibitor Debio 0932

Curis, Inc. (NASDAQ: CRIS) announced today that its licensee Debiopharm S.

Curis Publishes Preclinical CUDC-101 Data In Cancer Research

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a research paper describing the biological...

Curis Presents Preclinical Data On CU-906 At AACR 101st Annual Meeting 2010

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that data provided in a presentation entitled,...

Curis To Present At The 17th Annual Future Leaders In The Biotech Industry Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the company will be presenting at the 17 th...

Curis To Present At The ROTH Capital Partners 22nd Annual OC Growth Stock Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the ROTH...

Curis To Present At The 30th Annual Cowen Healthcare Conference

Curis To Present At The 30th Annual Cowen Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 30th...

Curis To Present At The RBC Capital Markets Healthcare Conference

Curis To Present At The RBC Capital Markets Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the RBC...

Curis Announces Chugai’s Exercise Of Japanese Development Rights For GDC-0449

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that Chugai Pharmaceutical Co.

Curis To Release Fourth Quarter And Year-end 2009 Financial Results And Hold Conference Call On February 25, 2010

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its fourth quarter financial results on ...

Curis Achieves Milestone Under Hsp90 Collaboration With Debiopharm

Curis, Inc. (NASDAQ: CRIS), announced today that its licensee Debiopharm S.

Curis Publishes CUDC-101 Medicinal Chemistry Data

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the...

Curis To Present At The 12th Annual BIO CEO & Investor Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 12th...

Curis, PharmAthene: Midday Volume Plays

Curis, PharmAthene: Midday Volume Plays

Several stocks trading near $5 were moving on above-average volume during Friday's session.

TheStreet Quant Rating: D- (Sell)